Latest filing published 29 Jul 2026 for Sarepta Therapeutics, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Filings by Michael Severino span 4 companies, the busiest being AbbVie Inc., Avantor, Inc. and Sarepta Therapeutics, Inc. Over a trading history stretching from 29 February 2016 to 28 July 2026, the count stands at 39 filings.
No open-market purchase appears, only 5 sales worth €13.8M. Besides market trades, the filings include 29 share grants and 4 option exercises.
The newest entry dates from 29 July 2026: a share grant, in Sarepta Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations